A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points

Ruben A Mesa; Heather Powell; Terra Lasho; Goron W DeWald; Rebecca McClure; Ayalew Tefferi

A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points

Haematologica. 2006 Mar;91(3):415-6.

Authors

Ruben A Mesa, Heather Powell, Terra Lasho, Goron W DeWald, Rebecca McClure, Ayalew Tefferi

PMID: 16531268

Abstract

Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.

Publication types

Comparative Study
Letter

MeSH terms

Humans
Janus Kinase 2
Longitudinal Studies
Mutation*
Phenylalanine / genetics
Primary Myelofibrosis / enzymology*
Primary Myelofibrosis / genetics*
Primary Myelofibrosis / pathology
Protein-Tyrosine Kinases / biosynthesis
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / biosynthesis
Proto-Oncogene Proteins / genetics*
Up-Regulation / genetics
Valine / genetics

Substances

Proto-Oncogene Proteins
Phenylalanine
Protein-Tyrosine Kinases
JAK2 protein, human
Janus Kinase 2
Valine